ClinicalTrials.gg
CompletedNCT03186209Updated Apr 24, 2024Results posted

Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)

A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 79 sites in 4 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
695
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
5th of 39
695 · median 128
Started
2017
with 3 others
Phase 3
20 of 39
1 open now
Registered
21st of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 5th largest by enrollment, is one of 4 that started in 2017, is one of 20 in phase 3, and was the 21st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting β2-agonist (ICS-LABA) with or without oral corticosteroids and additional asthma controllers.

Read the detailed description

Approximately 666 patients will be randomised. Patients will be stratified by country/region, age group (adult or adolescent), and peripheral blood eosinophil count at time of Visit 1 (\<300 or ≥300 cells/μL).All the patients will be randomised to either placebo or benralizumab (1:1 ratio) for a 48-weeks treatment, every 4 weeks for the first 3 doses and then every 8 weeks thereafter.

03

Conditions studied

  • Asthma

Keywords

  • Asthma,
  • Bronchial Diseases,
  • Respiratory Tract Diseases,
  • Lung Diseases,
  • Obstructive Lung Diseases
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Written , and assent when applicable for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent[s]/guardian[s]) and according to international guidelines and/or applicable local guidelines.
  2. Female and male aged 12 to 75 years, inclusively, at the time of Visit 1. For those patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be considered an adolescent for the purposes of this trial.
  3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (>250μg fluticasone propionate dry powder formulation equivalents total daily dose) and a LABA, for at least 6 months prior to Visit 1.
  4. Additional maintenance asthma controller medications that are locally approved in a country for the treatment of asthma (e.g., leukotriene receptor antagonists (LTRAs), tiotropium, chromone, theophylline, oral ), and have been used for at least 30 days prior to Visit 1 are allowed.
  5. At least 2 documented asthma exacerbations in the 12 months prior to the date informed consent, and assent when available, during the treatment of medium-to-high dose ICS-LABA that required use of a systemic corticosteroid or a temporary increase from the patient's usual maintenance dose of oral corticosteroid. For patients who are re-screened within 30 days of their screen failure date, the calculation of the 12 month period should be done from the original informed consent, and assent when applicable date.
  6. Documented post-bronchodilator (post-BD) reversibility in of >12% and >200 mL in FEV1 within 12 months prior to Visit 1. If historical documentation is not available, reversibility must be demonstrated and documented at Visit 2.
  7. Fulfilment of at least 1 of the following conditions over the 7 days prior to randomization:

    • >2 days with a daytime or night time symptoms score >1
    • Rescue Short-acting β2 agonist (SABA) use on >2 days
    • ≥1 nocturnal awakening due to asthma
  8. Pre-bronchodilator (Pre-BD) FEV1 of \<80% predicted (\<90% predicted for patients aged 12 to 17 years) at Visit 2.
  9. ACQ-6 score > = 1.5 at Visit 2.

Exclusion Criteria:

  1. Known history of pulmonary disease other than asthma (e.g., active lung infection, (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g,. allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).
  2. Known history of any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study.
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent, and assent when applicable, is obtained or during the screening period.
  4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study.
  5. Current smokers or former smokers with a smoking history of > 10 pack-years.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
695 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Benralizumab administered subcutaneously

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously

    Biological: Placebo

Interventions

  • BiologicalBenralizumab

    Benralizumab subcutaneously on study week 0 until study week 40 inclusive.

  • BiologicalPlacebo

    Placebo subcutaneously on study week 0 until study week 40 inclusive.

06

What researchers measure

Primary outcomes

  1. Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL

    Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups

    Time frame: From randomization through Study Week 48

Secondary outcomes

  1. Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)

    Time frame: From randomization through Study Week 48

  2. Change From Baseline at Week 48 in Total Asthma Symptom Score for for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.

    Time frame: From randomization through Study Week 48

  3. Change From Baseline at Week 48 in Total Asthma Rescue Medication Use for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Change from baseline at week 48 in total rescue medication use (number of puffs/day)

    Time frame: From randomization through Study Week 48

  4. Change From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Change from baseline at week 48 in morning PEF

    Time frame: From randomization through Study Week 48

  5. Change From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Change from baseline at week 48 in evening PEF

    Time frame: From randomization through Study Week 48

  6. Change From Baseline at Week 48 in the Proportion of Night Awakening Due to Asthma and Requiring Rescue Medication for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Change from baseline at Week 48 in proportion of night awakening due to asthma and requiring rescue medication

    Time frame: From randomization through Study Week 48

  7. Change From Baseline at Week 48 in Asthma Control Questionnaire 6 (ACQ-6) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses.

    Time frame: From randomization through Study Week 48

  8. Time to First Asthma Exacerbation for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Time to first asthma exacerbation over 48-week treatment period

    Time frame: From randomization through Study Week 48

  9. Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Number and percentage of patients with at least one exacerbation over 48-week treatment period

    Time frame: From randomization through Study Week 48

  10. Change From Baseline at Week 48 in Total Score of St. George's Respiratory Questionnaire (SGRQ) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    The SGRQ is a 50-item PRO instrument developed to measure the HRQoL of patients with airway diseases. The questionnaire is divided into two parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall HRQoL. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible HRQoL and 0 indicates the best possible HRQoL.

    Time frame: From randomization through Study Week 48

  11. Annual Asthma Exacerbation Rate Associated With an Emergency Room/Urgent Care Visit or a Hospitalization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Annual asthma exacerbation rate associated with an emergency room/urgent care visit or a hospitalization over 48-week treatment period

    Time frame: From randomization through Study Week 48

  12. Number and Percentages of Asthma Specific Health Care Resource Utilization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Asthma specific health care resource utilization over 48-week treatment period.

    Time frame: From randomization through Study Week 48

  13. The Pharmacokinetics (PK) of Benralizumab as Assessed by Trough Concentration

    PK trough concentrations at each visit

    Time frame: week 0, week 24, week 48

  14. The Immunogenicity of Benralizumab as Assessed by the Presence of Anti-drug Antibodies (ADAs)

    Anti-drug antibodies (ADA) responses at baseline and post baseline.

    Time frame: Pre-treatment until end of 48-week end of treatment

  15. Percent Change From Baseline at Week 48 in Blood Eosinophil Levels for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

    Percent change from baseline at Week 48 in blood eosinophil levels

    Time frame: From randomization through Study Week 48

Other outcomes

  1. Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL

    Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups

    Time frame: From randomization through Study Week 48.

  2. Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL

    Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)

    Time frame: From randomization through Study Week 48

  3. Change From Baseline at Week 48 in Total Asthma Symptom Score for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL

    Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.

    Time frame: From randomization through Study Week 48

07

Results

Posted Apr 24, 2024

Participant flow

695 participants were randomized to receive treatment in study D3250C00036 (MIRACLE) with Benralizumab or placebo. All the 695 randomized participants received treatment with study drug.

Participant flow — Overall Study
MilestoneBenralizumab 30 mgPlacebo
Started348347
Dosed348347
Completed331321
Not completed1726
Withdrew: Withdrawal by subject1122
Withdrew: Pregnancy10
Withdrew: Adverse event40
Withdrew: V18 skipped due to logistics reason10
Withdrew: Pi decided to discontinue the study due to the lack of crc resources02
Withdrew: Fail to meet randomization criteria01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryAnnual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL

Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups

Time frame:
From randomization through Study Week 48
Reported as:
Least squares mean · events/patient-year
Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL
events/patient-yearBenralizumab 30 mgPlacebo
Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL0.49 (0.33 to 0.72)1.88 (1.35 to 2.61)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = <0.0001 (Multiplicity protected by hierarchy testing procedure. First in line hypothesis testing, requiring p-value \<0.05.) · Rate ratio: 0.26 · 95% CI 0.19 to 0.36Model with covariates: treatment group, region (China/Non-China), number of exacerbations in previous year, use of maintenance oral corticosteroids
SecondaryChange From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Liter
Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
LiterBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL0.333 ± 0.44990.103 ± 0.4841
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Test after significant primary endpoint. Two secondary endpoints (change in FEV1 and total asthma symptom score) using Holm's procedure; smaller p-value to be \<0.025, and larger p-value to be \<0.05.) · Mean difference (final values): 0.25 · 95% CI 0.17 to 0.34Model includes Treatment, baseline pre-bronchodilator FEV1, region, use of maintenance oral corticosteroids, visit, and treatment by visit
SecondaryChange From Baseline at Week 48 in Total Asthma Symptom Score for for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline at Week 48 in Total Asthma Symptom Score for for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Scores on a scaleBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Total Asthma Symptom Score for for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL-1.07 ± 1.126-0.80 ± 1.129
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.0126 (Test after significant primary endpoint. Two secondary endpoints (change in FEV1 and total asthma symptom score) using Holm's procedure; smaller p-value to be \<0.025, and larger p-value to be \<0.05.) · Mean difference (final values): -0.25 · 95% CI -0.45 to -0.05Model includes Treatment, baseline total asthma symptom score, region, use of maintenance oral corticosteroids, visit, and treatment by visit
SecondaryChange From Baseline at Week 48 in Total Asthma Rescue Medication Use for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Change from baseline at week 48 in total rescue medication use (number of puffs/day)

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Puffs/day
Change From Baseline at Week 48 in Total Asthma Rescue Medication Use for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Puffs/dayBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Total Asthma Rescue Medication Use for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL-0.85 ± 1.865-0.89 ± 2.213
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.1835 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): -0.17 · 95% CI -0.42 to 0.08Model includes Treatment, baseline total asthma rescue medication use, region, use of maintenance oral corticosteroids, visit, treatment\*visit
SecondaryChange From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Change from baseline at week 48 in morning PEF

Time frame:
From randomization through Study Week 48
Reported as:
Mean · L/min
Change From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
L/minBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL54.194 ± 86.396312.995 ± 68.7947
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): 38.66 · 95% CI 24.24 to 53.07Model includes Treatment, baseline morning PEF, region, use of maintenance oral corticosteroids, visit, and treatment by visit
SecondaryChange From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Change from baseline at week 48 in evening PEF

Time frame:
From randomization through Study Week 48
Reported as:
Mean · L/min
Change From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
L/minBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL45.661 ± 85.46427.989 ± 68.0632
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): 35.85 · 95% CI 21.52 to 50.18Model includes Treatment, baseline evening PEF, region, use of maintenance oral corticosteroids, visit, and treatment by visit
SecondaryChange From Baseline at Week 48 in the Proportion of Night Awakening Due to Asthma and Requiring Rescue Medication for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Change from baseline at Week 48 in proportion of night awakening due to asthma and requiring rescue medication

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Proportion of nights
Change From Baseline at Week 48 in the Proportion of Night Awakening Due to Asthma and Requiring Rescue Medication for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Proportion of nightsBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in the Proportion of Night Awakening Due to Asthma and Requiring Rescue Medication for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL-0.15 ± 0.220-0.15 ± 0.260
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.3385 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): -0.01 · 95% CI -0.03 to 0.01Model includes Treatment, baseline proportion of nights awakening, region, use of maintenance oral corticosteroids, visit, and treatment by visit
SecondaryChange From Baseline at Week 48 in Asthma Control Questionnaire 6 (ACQ-6) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses.

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline at Week 48 in Asthma Control Questionnaire 6 (ACQ-6) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Scores on a scaleBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Asthma Control Questionnaire 6 (ACQ-6) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL-1.22 ± 0.901-0.79 ± 0.962
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): -0.43 · 95% CI -0.58 to -0.28Model includes Treatment, baseline ACQ-6 score, use of maintenance oral corticosteroids, visit, and treatment by visit
SecondaryTime to First Asthma Exacerbation for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Time to first asthma exacerbation over 48-week treatment period

Time frame:
From randomization through Study Week 48
Reported as:
Median · Days
Time to First Asthma Exacerbation for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
DaysBenralizumab 30 mgPlacebo
Time to First Asthma Exacerbation for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uLNA (NA to NA)227 (146 to NA)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Regression, Cox · p = <0.0001 (Nominal p-value. Not multiplicity protected by testing procedure.) · Hazard ratio (hr): 0.32 · 95% CI 0.23 to 0.43model including covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids
SecondaryNumber and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Number and percentage of patients with at least one exacerbation over 48-week treatment period

Time frame:
From randomization through Study Week 48
Reported as:
Count of participants · Participants
Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
ParticipantsBenralizumab 30 mgPlacebo
Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL55125
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Nominal p-value. Not multiplicity protected by testing procedure.) · Odds ratio (or): 0.28 · 95% CI 0.19 to 0.42Controlling for region, number of exacerbations in the previous year (2, \>=3), use of OCS
SecondaryChange From Baseline at Week 48 in Total Score of St. George's Respiratory Questionnaire (SGRQ) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

The SGRQ is a 50-item PRO instrument developed to measure the HRQoL of patients with airway diseases. The questionnaire is divided into two parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall HRQoL. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible HRQoL and 0 indicates the best possible HRQoL.

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline at Week 48 in Total Score of St. George's Respiratory Questionnaire (SGRQ) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Scores on a scaleBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Total Score of St. George's Respiratory Questionnaire (SGRQ) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL-23.24 ± 20.509-14.75 ± 21.838
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): -9.19 · 95% CI -12.79 to -5.60Model with covariates: treatment group, baseline SGRQ total score, region, use of maintenance oral corticosteroids, visit, and treatment by visit
SecondaryAnnual Asthma Exacerbation Rate Associated With an Emergency Room/Urgent Care Visit or a Hospitalization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Annual asthma exacerbation rate associated with an emergency room/urgent care visit or a hospitalization over 48-week treatment period

Time frame:
From randomization through Study Week 48
Reported as:
Least squares mean · events/patient-year
Annual Asthma Exacerbation Rate Associated With an Emergency Room/Urgent Care Visit or a Hospitalization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
events/patient-yearBenralizumab 30 mgPlacebo
Annual Asthma Exacerbation Rate Associated With an Emergency Room/Urgent Care Visit or a Hospitalization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL0.06 (0.04 to 0.11)0.14 (0.09 to 0.20)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.0222 (Nominal p-value. Not multiplicity protected by testing procedure.) · Rate ratio: 0.46 · 95% CI 0.24 to 0.90Model includes Treatment, use of maintenance oral corticosteroids, categorical variable of ER/UC or hospitalization exacerbations during previous year
SecondaryNumber and Percentages of Asthma Specific Health Care Resource Utilization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Asthma specific health care resource utilization over 48-week treatment period.

Time frame:
From randomization through Study Week 48
Reported as:
Count of participants · Participants
Number and Percentages of Asthma Specific Health Care Resource Utilization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
ParticipantsBenralizumab 30 mgPlacebo
Hospitalisations621
Emergency Department Visits1112
Unscheduled Outpatient Visits5399
Home Visits12
Telephone Calls3571
Ambulance Transports22
Advanced Pulmonary Function Test48
SecondaryThe Pharmacokinetics (PK) of Benralizumab as Assessed by Trough Concentration

PK trough concentrations at each visit

Time frame:
week 0, week 24, week 48
Reported as:
Geometric mean · ng/mL
The Pharmacokinetics (PK) of Benralizumab as Assessed by Trough Concentration
ng/mLBenralizumab 30 mgPlacebo
Week 00 ± 0—
Week 24137.914 ± 432.419—
Week 48123.476 ± 395.951—
SecondaryThe Immunogenicity of Benralizumab as Assessed by the Presence of Anti-drug Antibodies (ADAs)

Anti-drug antibodies (ADA) responses at baseline and post baseline.

Time frame:
Pre-treatment until end of 48-week end of treatment
Reported as:
Count of participants · Participants
The Immunogenicity of Benralizumab as Assessed by the Presence of Anti-drug Antibodies (ADAs)
ParticipantsBenralizumab 30 mgPlacebo
ADA positive at any time, including baseline and/or post-baseline (ADA prevalence)586
Treatment-emergent ADA positive, including treatment-induced and treatment-boosted ADA positive582
Treatment-induced ADA positive562
Treatment-boosted ADA positive20
ADA positive at both baseline and at least one post-baseline assessment22
ADA positive at baseline only02
ADA persistently positive401
ADA transiently positive161
ADA positive with maximum titre > median of maximum titres252
ADA positive with maximum titre <= median of maximum titres334
nAb prevalence (nAb positive at any time, including baseline and/or post-baseline)551
nAb incidence551
SecondaryPercent Change From Baseline at Week 48 in Blood Eosinophil Levels for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL

Percent change from baseline at Week 48 in blood eosinophil levels

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Percent change
Percent Change From Baseline at Week 48 in Blood Eosinophil Levels for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL
Percent changeBenralizumab 30 mgPlacebo
Percent Change From Baseline at Week 48 in Blood Eosinophil Levels for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL-80.6 ± 34.6542.3 ± 380.86
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): -119.31 · 95% CI -169.78 to -68.84model includes treatment , baseline eosinophil count, region, use of maintenance oral corticosteroids, visit, and treatment by visit
Other pre-specifiedAnnual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL

Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups

Time frame:
From randomization through Study Week 48.
Reported as:
Least squares mean · events/patient-year
Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL
events/patient-yearBenralizumab 30 mgPlacebo
Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL0.72 (0.49 to 1.06)0.87 (0.61 to 1.24)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Negative binomial · p = 0.4519 (Nominal p-value. Not multiplicity protected by testing procedure.) · Rate ratio: 0.83 · 95% CI 0.51 to 1.35Model with covariates: treatment group, region (China/Non-China), number of exacerbations in previous year, use of maintenance oral corticosteroids
Other pre-specifiedChange From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL

Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Liter
Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL
LiterBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL0.178 ± 0.40680.045 ± 0.3626
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.0214 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): 0.12 · 95% CI 0.02 to 0.22Model includes Treatment, baseline pre-bronchodilator FEV1, region, use of maintenance oral corticosteroids, visit, and treatment by visit
Other pre-specifiedChange From Baseline at Week 48 in Total Asthma Symptom Score for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL

Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.

Time frame:
From randomization through Study Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline at Week 48 in Total Asthma Symptom Score for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL
Scores on a scaleBenralizumab 30 mgPlacebo
Change From Baseline at Week 48 in Total Asthma Symptom Score for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL-0.97 ± 1.260-0.75 ± 1.105
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed Models Analysis · p = 0.1589 (Nominal p-value. Not multiplicity protected by testing procedure.) · Mean difference (final values): -0.21 · 95% CI -0.51 to 0.08Model includes Treatment, baseline total asthma symptom score, region, use of maintenance oral corticosteroids, visit, and treatment by visit

Adverse events

Collected over From initial dose of the study treatment to the end of study, i.e., up to 56 weeks of follow-up.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab 30 mg0/348 (0%)44/348 (12.6%)194/348 (55.7%)
Placebo0/347 (0%)63/347 (18.2%)194/347 (55.9%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventBenralizumab 30 mgPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders12/34833/347
PneumoniaInfections and infestations3/3486/347
Pneumonia bacterialInfections and infestations3/3483/347
CataractEye disorders1/3483/347
Nasal polypsRespiratory, thoracic and mediastinal disorders3/3481/347
Lower respiratory tract infectionInfections and infestations0/3482/347
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/3482/347
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3482/347
Chronic sinusitisInfections and infestations2/3480/347
Rotator cuff syndromeMusculoskeletal and connective tissue disorders2/3480/347
Most frequent other events
Showing 10 of 13
Most frequent other events
EventBenralizumab 30 mgPlacebo
Upper respiratory tract infectionInfections and infestations120/348120/347
NasopharyngitisInfections and infestations28/34833/347
BronchitisInfections and infestations11/34827/347
Rhinitis allergicRespiratory, thoracic and mediastinal disorders22/34815/347
PyrexiaGeneral disorders18/3489/347
PneumoniaInfections and infestations9/34816/347
PharyngitisInfections and infestations13/34813/347
HypertensionVascular disorders7/34813/347
RhinitisInfections and infestations13/3486/347
Urinary tract infectionInfections and infestations9/34812/347

Baseline characteristics

Full analysis set, all participants who were randomized and received at least one investigational product (IP), Benralizumab or Placebo.

Age, Continuous
Age, Continuous(years)Benralizumab 30 mgPlaceboTotal
Mean51.1 ± 11.5651.0 ± 12.5651.1 ± 12.06
Age, Customized
Age, Customized(Participants)Benralizumab 30 mgPlaceboTotal
>=12 - <18 years101
>=18 - <65 years299295594
>=65 - <=754852100
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 30 mgPlaceboTotal
Female221207428
Male127140267
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab 30 mgPlaceboTotal
Hispanic or Latino000
Non-Hispanic or Latino348347695
Asian348347695
08

Study locations

79 sites
  • Research Site
    Baotou, 14010, China
  • Research Site
    Beijing, 100020, China
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100037, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changsha, 410004, China
  • Research Site
    Changsha, 410015, China
  • Research Site
    Changzhi, 46000, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chengdu, 611130, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Foshan, 528000, China
  • Research Site
    Ganzhou, 341000, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510150, China
  • Research Site
    Guangzhou, 510180, China
  • Research Site
    Guiyang, 550004, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Hohhot, 010017, China
  • Research Site
    Hohhot, 10050, China
  • Research Site
    Jining, 272029, China
  • Research Site
    Kunming, 650032, China
  • Research Site
    Kunming, 650051, China
  • Research Site
    Lishui, 323000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 2100008, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Neijiang, 641000, China
  • Research Site
    Qingdao, 110016, China
  • Research Site
    Qingdao, 266000, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200072, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shanghai, 201199, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenyang, 110015, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Taizhou, 225300, China
  • Research Site
    Wanzhou, 404000, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xiangtan, 411100, China
  • Research Site
    Xinxiang, 453002, China
  • Research Site
    Xuzhou, 221006, China
  • Research Site
    Xuzhou, 221009, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Yinchuan, 750001, China
  • Research Site
    Yinchuan, 750004, China
  • Research Site
    Zhanjiang, 524001, China
  • Research Site
    Zhuhai, 519099, China
  • Research Site
    Zunyi, 563100, China
  • Research Site
    Bucheon-si, 14584, Korea, Republic of
  • Research Site
    Busan, 49241, Korea, Republic of
  • Research Site
    Cheonan, 330-715, Korea, Republic of
  • Research Site
    Daejeon, 35365, Korea, Republic of
  • Research Site
    Gwangju, 61469, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 03181, Korea, Republic of
  • Research Site
    Seoul, 03312, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 04763, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 08308, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Uijeongbu-si, 11765, Korea, Republic of
  • Research Site
    Wonju, 26426, Korea, Republic of
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Taipei, 114, Taiwan
  • Research Site
    Taoyuan City, 333, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jan 2023, 64 months.

Results were first posted in Apr 2024, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 64 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2017
First posted
Jun 14, 2017
StartActual
Sep 7, 2017
Primary completionActual
Jan 30, 2023
CompletionActual
Jan 30, 2023
Results first posted
Apr 24, 2024
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03186209
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 14, 2017
Start date
Sep 7, 2017
Primary completion
Jan 30, 2023
Completion
Jan 30, 2023
Results posted
Apr 24, 2024
Last update
Apr 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion